Strategic partnerships ID SOLUTIONS has recent collaboration momentum with Oncobit and a commercial partnership with QIAGEN to expand digital PCR capabilities in oncology research, signaling opportunities to co-sell integrated diagnostic workflows and shared marketing.

Oncology specialization Focused on circulating tumor DNA and liquid biopsy as well as solid tumor DNA typing, the company targets oncology diagnostics with standardized tools, presenting a clear value proposition for labs aiming to enhance molecular typing and precision oncology programs.

Technology stack Existing tech footprint includes iCIMS, HubSpot, WordPress, Shopify, and analytics tools, suggesting ready-made channels for lead capture, CRM-driven outreach, partner onboarding, and digital marketing campaigns to accelerate and track sales efforts.

Growth potential Revenue is currently under one million USD with a small to mid-size team, indicating opportunities to scale through expanded clinical partnerships, contract manufacturing, or licensing of standardized SOPs and custom development services.

Expansion readiness Recent media coverage of partnerships and a niche in precision oncology imply readiness to engage distributors and research institutions seeking digital PCR and liquid biopsy solutions, presenting a pathway for channel sales and strategic alliances.